期刊文献+

玻璃体腔注射康柏西普治疗渗出型老年性黄斑变性的疗效观察 被引量:3

下载PDF
导出
摘要 观察在渗出型老年性黄斑变性治疗中采用康柏西普玻璃体腔注射的临床疗效。选取104例单眼患病的渗出型老年性黄斑变性患者作为受试对象,采用随机序贯平衡法将其分为对照组与观察组,分别给予保守治疗和康柏西普玻璃体腔注射治疗。对比临床疗效、治疗前和治疗6个月后两组裸眼视力及黄斑中心凹视网膜厚度变化。两组疗效分布差异显著(P<0.05),且观察组总有效率为96.15%,远高于对照组的78.85%(P<0.05);治疗前两组裸眼视力及黄斑中心凹视网膜厚度均无显著差异(P>0.05),本组内治疗前后数据比较有显著性差异(P<0.05),且治疗后组间差异也有显著性(P<0.05)。在渗出型老年性黄斑变性治疗中采用玻璃体腔注射康柏西普能够显著改善疗效,提高裸眼视力,还可显著降低黄斑中心凹视网膜厚度。
作者 宋梅花
机构地区 孟州市人民医院
出处 《现代诊断与治疗》 CAS 2017年第22期4174-4175,共2页 Modern Diagnosis and Treatment
  • 相关文献

参考文献4

二级参考文献37

  • 1蒋瑶祁,彭辉灿.VEGF家族及其受体与视网膜新生血管形成[J].国际眼科杂志,2006,6(5):1113-1116. 被引量:17
  • 2Rudnicka AR, Jarrar Z, Wormald R, et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis [J]. Ophthalmology, 2012, 119(3): 571-580.
  • 3American Academy of Ophthalmology Retina Panel. Preferred Practice Pattern? Guidelines: comprehensive adult medical eye evaluation E EB/OL]. San Francisco: American Academy of Ophthalmology, 2010 [ 2010-09-11 ]. http://one. Aao. Org/ CE/ Practice Guidelines/ PPP. Asox? o: 1.
  • 4Takashi U, Yasuo N, Takuhiro Y, et al. Systemic vascular safety of ranibizumah for age-related macular degeneration: systematic review and meta-analysis of randomized trials [J]. Ophthalmology, 2014, 121(11) :2193-2203.
  • 5Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration [J]. Clin Ophthalmol, 2008, 2(2) :377-388.
  • 6Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12- month randomized phase 2 study: AURORA study [J]. Ophthalmology, 2014, 121(9) :1740-1747.
  • 7Wang Q, Li T,Wu Z, et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo[J/OL]. PLoS One, 2013, 8(8) : 70544[2013-08-12]. http://dx, plos. org/10. 1371/ journal, pone. 0070544.
  • 8Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration [J]. N Engl J Med, 2006, 355:1419-1431.
  • 9Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study [J]. Ophthalmology, 2009, 116(1) :57-65.
  • 10Singer MA, Awh CC, Sadda S, et al. HORIZON: an openlabel extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration [J]. Ophthalmology, 2012, 119(6) :1175-1183.

共引文献95

同被引文献27

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部